Physician profile

Patrick Correlli

Physician Assistant · Randallstown, MD

NPI 1437480092

$559.64

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$318.47

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Scpharmaceuticals INC. $240.90 2023
Nuwellis, INC. $155.00 2022-2023 Aquadex Smartflow Console
Abbott Laboratories $77.69 2021
Lexicon Pharmaceuticals, INC. $31.45 2023 Inpefa
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $19.84 2021-2023 Lifevest
Bayer Healthcare Pharmaceuticals INC. $18.84 2023
Novo Nordisk INC $15.92 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Patrick Correlli

$559.64

in general payments reported 2019-2025

Years
2021-2023
Top company
Scpharmaceuticals INC.

https://glasscript.com/doctor/10511518/patrick-correlli

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.